○Hiroaki Yoshikawa1, Yosikazu Nakamura2, Nagato Kuriyama3, Hiroyuki Murai4, Yasunari Sakai5, Yoshiko Nomura6, Yumi Adachi1, Kazuo Iwasa7, Yutaka Furukawa8, Akitaka Higashi9, Makoto Matsui10 (1.Kanazawa University Health Service Center, Japan, 2.Jichi Medical University Department of Public Health, 3.Kyoto Prefectural University of Medicine Department of Epidemiology for Community Health and Medicine, 4.International University of Health and Welfare Department of Neurology, 5.Kyushu University Department of Pediatrics, 6.Nomura Yoshiko Pediatric Neurology Clinic, 7.Ishikawa Prefectural Nursing University, 8.Kanazawa University Department of Neurology and Neurobiology of Aging, 9.Kanazawa University Information Media Center, 10.Kanazawa Medical University Department of Neurology)
Session information
Oral Session
[O-17] Oral Session 17 Neuromuscular junction disorders
Thu. May 20, 2021 9:45 AM - 10:45 AM Room 07 (ICC Kyoto 1F Room D)
Chair:Head Quarters Office
○Asato Tsuji, Norio Chihara, Masaya Togo, Hiroaki Sekiya, Takehiro Ueda, Kenji Sekiguchi, Riki Matsumoto (Division of Neurology, Kobe University Graduate School of Medicine, Japan)
○Hiroyuki Akamine1, Akiyuki Uzawa1, Yuta Kojima1, Yukiko Ozawa1, Manato Yasuda1, Yosuke Onishi1, Naoki Kawaguchi2, Keiichi Himuro3, Satoshi Kuwabara1 (1.Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan, 2.Department of Neurology, Dowa Institute of Clinical Neuroscience, Neurology Clinic Chiba, Chiba, Japan, 3.Department of Neurology, Matsudo Neurology Clinic, Chiba, Japan)
○Kimiaki Utsugisawa1, Shigeaki Suzuki2, Takeshi Hayashi3, Yuji Fukamizu3, Murai Hiroyuki4 (1.Department of Neurology, Hanamaki General Hospital, Japan, 2.Department of Neurology, Keio University School of Medicine, 3.Medical Affairs, Alexion Pharma GK, 4.Department of Neurology, International University of Health and Welfare)